Asthma

IL-4, IL-13, AND IL-5 ARE DRIVERS OF SYSTEMIC TYPE 2 INFLAMMATION

Eosinophilic inflammation has multiple drivers^1,2

The Role of Mucus Plugging in Asthma and Its Clinical Burden

Understanding Airway Obstruction: The Role of Mucus Plugging in Asthmatic Disease

Assessing Pediatric Lung Function

Pediatric Management

Mucus Plugging Is a Key Component of Remodeling in Asthma, Leading to Fixed Airway Obstruction

VESTIGE study

VESTIGE Trial Results: Dupilumab in Type 2 Asthma

Prevalence of Asthma

Asthma Control Tests (ACT) overview

FeNO Is a Clinically Useful Biomarker of Type 2 Inflammation in Pediatric Patients With Asthma

When do you discuss Biologic treatment with your Asthma patients?

Severe Asthma Biomarker's

The Vital Role of Lung Function in Asthma Care

Why is it important to look for Type 2 inflammation in patients with Asthma?

Sever Asthmatic patients with OCS

How do you choose the right Biologic for a particular Asthma patients?

What challenges do you face when treating patients with Type 2 inflammation?

How do you balance the cost of Biologics with the value they can bring to patients?

How Type 2 inflammation affect patients with Asthma?

How does Dupixent improve Asthma control and quality of live for Pediatric Patients?

Fractional exhaled nitric oxide (Feno)

Asthma Clinical Remission: The Benchmarks for Eliminating Airway Inflammation and Symptoms

Consider Dupixent for Asthmatic patients with OCS use

Airway Hyperresponsiveness in Asthma

ON-TREATMENT ASTHMA REMISSION: MOVING BEYOND CONTROL

Discover a solution to control mixed Eosinophilic and Allergic Asthma

About Type 2 Inflammation – Asthma

Dupixent® (dupilumab) Mechanism of Action

How does Dupixent support lung function improvement in Pediatric Asthma?

Consider Dupixent for Asthmatic patients with high EOS